depression

9511213674_31a3c06cc7_z

Introduction

Clinical, unipolar depression is more than just feeling low for a day or two.

Depression is characterised as episodes of sadness, loss of interest and pleasure, often including feelings of low self-worth. Depression can also include a range of physiological symptoms, such as fatigue, pain, diminished appetite, lack of interest in sex, disturbed sleep, and poor concentration.

The World Health Organisation estimates that, globally, as many as 350 million people are affected at any given time, with one person in 20 reporting an episode of depression in a 12 month period (in a global sample of 17 countries). They describe depression as the leading cause of disability worldwide.

What we know already

We know that, despite the considerable global burden of depression, not everybody receives treatment, with figures ranging from 50% to 10% in less developed countries.

Evidence suggests that combined psychological and pharmacological treatments seem to work well. Broadly, we know that psychotherapies work in many cases – but not every time. We know that neurochemical factors, such as serotonergic dysfunction, play an important role in depression, which goes a long way in explaining the efficacy of SSRI treatments.

We also know that depression has a nasty habit of recurrence, and some psychological interventions, such as Mindfulness-Based Cognitive Therapy (MBCT) is recommended particularly for people who have experienced multiple episodes of depression, but not are currently severely depressed.

We know that people living with chronic physical illness are more likely to experience depression, and this combination is linked with poorer clinical outcomes.

Importantly though, we know that people with depression can still enjoy themselves, and a common misconception in depression is that people feel totally awful all of the time.

Areas of uncertainty

There is much still to determine. For example, we know that depression is hereditable, however the extent of heredity versus environmental influences are unclear.

We are also unsure as to the precise mechanisms that determine those who respond best to treatments, be they psychopharmacological, or psychological, or both.

What’s in the pipeline?

Despite advances in our understanding of depression, and how it is treated, it remains a highly recurrent difficulty, with many people not achieving complete remission between episodes.

Preventative interventions, either physiological, or psychological, may improve people’s resilience to depression, particularly those identified as being highly prone.

References

Cuijpers, P. (2015). Psychotherapies for adult depression: recent developments. Current Opinion in Psychiatry, 28, 24-29. [Abstract]

Naylor, C., Parsonage, M., McDaid, D., Knapp, M., Fossey, M. and Galea, A. (2012) Long-term conditions and mental health: the cost of co-morbidities. The King’s Fund, London, UK [PDF]

World Health Organisation (2015).Factsheet 369: Depression [Link]

Photo Credits

Sascha Kohlmann CC BY 2.0

Acknowledgement

Written by: Patrick Kennedy-Williams
Reviewed by:
Last updated: Nov 2015
Review due: Sep 2016

Our depression Blogs

Aripiprazole for treatment-resistant depression in older adults

16407815325_c4bc936054_k

Sarsha Wilson publishes her debut blog about a recent RCT on the efficacy, safety and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in later life.

[read the full story...]

CBT plus medication for treatment-resistant depression: the CoBalT RCT long-term follow-up

8573647118_6444988740_k

Sarah McDonald considers the findings of the CoBalT RCT long-term follow-up, which finds that CBT plus antidepressants are clinically and cost effective for treatment-resistant depression in primary care.

[read the full story...]

Omega-3 fatty acids for depression: Cochrane find insufficient evidence to support use

1816877969_bc1e4ba980_b

Lisa Burscheidt summarises a recent Cochrane systematic review of Omega-3 fatty acids for depression in adults, which finds a lack of evidence to determine the effects of n-3PUFAs as a treatment for major depressive disorder.

[read the full story...]

Are Internet interventions cost-effective for mental health?

16844834832_f13124e85c_o

Chris Sampson looks at a systematic review of the economics of Internet interventions for common mental health problems such as depression and anxiety.

[read the full story...]

Psychotic-like experiences associated with self-harm, according to new systematic review, but further research is needed

15506836435_9703e67552_k

Katrina Witt critiques a recent systematic review of psychotic-like experiences and the risk of self-harm and suicide in the general population.

[read the full story...]

IPT and CBT best for depression in children and young people, says network meta-analysis

4929686071_970be30b8d_o

Laura Hemming summarises a recent network meta-analysis of psychotherapies for depression in children and young people, which finds that Interpersonal Psychotherapy (IPT) and Cognitive Behavioural Therapy (CBT) were significantly more efficacious than other psychotherapies at post-treatment and follow-up.

[read the full story...]

Work Capability Assessments linked with increase in suicides

13903379060_65bd06a926_k

Ian Cummins considers the findings of a recent longitudinal study that measures the impact that welfare reform and disability assessments have had on mental illness and rates of suicide.

[read the full story...]

All in the mindfulness? Reflections on the Mindful Nation report

5259784851_6708fc11b5_b

André Tomlin considers the recommendations for health service delivery and research from the recent Mindful Nation report.

[read the full story...]